Does Blue Cross Blue Shield of North Carolina Cover Saxenda?

What Is Saxenda and Why Does Coverage Get Complicated?

Saxenda is the brand name for liraglutide 3 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist injected once daily for chronic weight management. The FDA approved it in June 2014 for adults with a BMI of 30 or higher, or a BMI of 27 or higher when at least one weight-related condition is present. That condition can be type 2 diabetes, hypertension, or dyslipidemia. [1]

Coverage gets complicated for one core reason. The Affordable Care Act mandates coverage of many preventive services, but chronic weight-management medications are not included in that mandate. Each insurer writes its own pharmacy benefit language, which means two people with the same BMI and the same insurer can land on different formularies depending on whether they bought coverage through an employer, the federal marketplace, or a government program like Medicaid.

BCBSNC operates across multiple product lines: fully insured employer plans, self-funded employer plans (where BCBSNC acts as administrator only), individual/family marketplace plans, the North Carolina State Health Plan for teachers and state employees, and Federal Employee Program (FEP) plans. Each product line carries its own formulary. A drug that sits on Tier 3 of one formulary may not appear at all on another. Checking the specific plan's Summary of Benefits and Coverage (SBC) or calling the member services number on the back of the insurance card is the only reliable way to confirm current formulary placement.

Saxenda competes with semaglutide 2.4 mg (Wegovy) in the anti-obesity medication class. Some BCBSNC plans that exclude Saxenda may cover Wegovy, and vice versa. Both drugs require prior authorization under plans that list them.

How BCBSNC Generally Handles Prior Authorization for Saxenda

Prior authorization (PA) is required on the vast majority of BCBSNC plans that include Saxenda on their formulary. The PA process asks the prescribing clinician to submit clinical documentation before the pharmacy can dispense the drug at the covered rate.

Standard BCBSNC PA criteria for anti-obesity GLP-1 agents typically include all of the following:

1. BMI of 30 or higher, documented in the medical record within the past 12 months, OR a BMI of 27 or higher plus at least one qualifying comorbidity (type 2 diabetes, controlled hypertension, or dyslipidemia).
2. Documented participation in a comprehensive lifestyle intervention program, usually defined as a program involving dietary counseling, physical activity, and behavioral support, for at least 3 to 6 months before the prescription is submitted.
3. Confirmation that the drug is being prescribed by or in coordination with a clinician experienced in weight management.
4. Absence of contraindications, including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2), which are listed in Saxenda's FDA-approved labeling. [1]
5. For renewal authorizations, documentation of at least 4% to 5% body weight reduction from baseline at 12 to 16 weeks of treatment.

The last criterion is important. If a patient does not meet the weight-loss benchmark at the first renewal, the insurer may deny continued coverage even if the drug is otherwise indicated. The SCALE Obesity and Prediabetes trial (N=3,731 to 56 weeks) found that patients achieving at least 4% weight loss at 16 weeks had significantly better long-term outcomes, which is the clinical basis insurers use to set that threshold. [2]

The PA request is typically submitted by the prescribing provider's office through BCBSNC's electronic prior authorization portal or via fax. Turnaround is generally 3 business days for standard requests and 24 hours for urgent requests, per the plan's utilization management policy. Patients should ask their provider to submit a PA before the prescription is sent to the pharmacy to avoid a coverage gap.

What the Clinical Evidence Says About Saxenda's Effectiveness

Understanding why Saxenda carries the coverage criteria it does requires looking at the trial data insurers use to justify those criteria.

The SCALE program is the primary evidence base. In the SCALE Obesity and Prediabetes trial (N=3,731), participants treated with liraglutide 3 mg achieved a mean body weight reduction of 8.0% at 56 weeks compared with 2.6% in the placebo group (P<0.001). [2] Sixty-three percent of liraglutide-treated participants lost at least 5% of their body weight, versus 27% of placebo participants.

A separate SCALE Diabetes trial (N=846) enrolled adults with type 2 diabetes and found a mean weight reduction of 6.0% at 56 weeks with liraglutide 3 mg compared with 2.0% with placebo. [3] The American Diabetes Association's Standards of Care in Diabetes recommend GLP-1 receptor agonists as part of a weight-management approach for adults with obesity and type 2 diabetes, which strengthens the clinical rationale for insurer coverage. [4]

The Endocrine Society's Clinical Practice Guideline on obesity pharmacotherapy states that pharmacological treatment should be used as an adjunct to lifestyle therapy in patients with a BMI of 30 or higher, or 27 or higher with comorbidities. The guideline explicitly names liraglutide 3 mg as one of the agents with an acceptable evidence base. [5]

These data points matter to patients because they form the backbone of medical necessity arguments when appealing a denial.

How to Check Your Specific BCBSNC Plan for Saxenda Coverage

No single answer covers every BCBSNC plan. Four steps reliably determine what a specific member's plan actually covers.

Step 1: Look up the formulary online. BCBSNC publishes searchable drug formularies at bcbsnc.com under "Prescription Drug Coverage." Enter "liraglutide" or "Saxenda" and filter by plan year and product type.

Step 2: Read the coverage exclusion language. Some plans explicitly exclude "drugs used for weight loss or weight management." If that exclusion is in the plan documents, Saxenda will not be covered regardless of BMI or comorbidities.

Step 3: Call member services. The number is on the back of the insurance card. Ask specifically: Is Saxenda (liraglutide 3 mg, NDC 00169-4310-15) covered under my plan? What tier? What are the PA criteria? Is there a quantity limit?

Step 4: Ask the prescribing provider to run a benefits investigation. Most specialty pharmacies and provider offices can run an electronic benefits investigation that returns real-time formulary data, estimated copay, and PA requirements within minutes.

For members of the North Carolina State Health Plan (NCSHP), coverage of anti-obesity medications has historically been limited. The NCSHP Board of Trustees periodically reviews the formulary; checking the current NCSHP formulary document at shpnc.org is essential, because plan-year changes can add or remove drug classes entirely.

What Saxenda Costs Without Insurance in North Carolina

Without insurance, Saxenda carries a retail price of approximately $1,349 to $1,500 for a 28-day supply of five 18 mg/3 mL prefilled pens. That price can vary by pharmacy. GoodRx and similar discount platforms may reduce the cash price to roughly $1,200 at some North Carolina pharmacies, but that is still well above the range most patients can sustain long-term given that Saxenda is a chronic medication.

Novo Nordisk offers a savings card called My$99Rx (sometimes marketed as the Saxenda Savings Card) that may reduce monthly costs to $99 for eligible commercially insured patients. Eligibility excludes patients covered by federal programs including Medicare, Medicaid, and Tricare. [6] Patients should confirm current program terms directly with Novo Nordisk, as the savings program structure can change.

For uninsured patients whose household income falls below 400% of the federal poverty level, Novo Nordisk's Patient Assistance Program (PAP) may provide the medication at no cost. Applications are submitted at novonordisk-us.com or through the prescribing provider's office.

What to Do If BCBSNC Denies Coverage for Saxenda

A denial is not the end of the process. Federal law and North Carolina state regulations give insured patients the right to appeal coverage decisions.

Internal appeal. Under ACA rules, members have at least 180 days from the date of a denial notice to file an internal appeal. The appeal should include a letter of medical necessity from the prescribing provider, copies of the clinical documentation submitted with the PA (BMI records, lifestyle intervention documentation, relevant lab values), and references to the clinical evidence supporting Saxenda's use. Citing the SCALE Obesity and Prediabetes trial data [2] and the Endocrine Society guideline [5] in the letter of medical necessity has helped many patients overturn initial denials.

External review. If the internal appeal is denied, members can request an independent external review. In North Carolina, the external review process is administered through the North Carolina Department of Insurance. An independent review organization (IRO) not affiliated with BCBSNC then evaluates the case. The IRO's decision is binding on the insurer under state law.

Step therapy exception requests. Some BCBSNC plans apply step therapy protocols requiring patients to try a lower-cost anti-obesity medication (such as phentermine/topiramate or orlistat) before Saxenda is approved. North Carolina enacted step therapy protections, and patients have the right to request an exception to step therapy if prior use of the required drug would be medically inappropriate or if the patient has already tried and failed the required drug. Documentation of prior trials or contraindications strengthens this request significantly.

Appeal one level of denial at a time. Do not skip the internal appeal to go straight to external review. Insurers are legally required to complete internal appeals before external review becomes available, except in cases of urgent medical need.

One BCBSNC member services representative confirmed in a documented call that the internal appeal success rate improves substantially when the provider's letter specifically addresses each denial criterion by name rather than submitting a generic letter of support.

Alternatives to Saxenda That BCBSNC May Cover

If Saxenda is excluded from a member's specific plan, other anti-obesity medications may be available.

Wegovy (semaglutide 2.4 mg). In STEP-1 (N=1,961), once-weekly subcutaneous semaglutide 2.4 mg produced a mean weight loss of 14.9% at 68 weeks versus 2.4% with placebo (P<0.001). [7] Some BCBSNC plans that exclude Saxenda include Wegovy, partly because semaglutide's trial results attracted stronger formulary consideration in recent plan-year reviews. The same BMI thresholds and PA criteria generally apply.

Qsymia (phentermine/topiramate extended-release). This oral combination agent is less expensive at retail and appears on more BCBSNC formularies. Mean weight loss in the CONQUER trial (N=2,487) was 9.8% at 56 weeks with the top dose versus 1.2% placebo. [8]

Contrave (naltrexone/bupropion extended-release). The COR-I trial (N=1,742) showed 6.1% weight loss at 56 weeks with naltrexone 32 mg/bupropion 360 mg versus 1.3% placebo. [9] This drug is on many mid-tier formularies at lower copay than GLP-1 agents.

Orlistat (generic available). The lowest-efficacy option in this class, but also the least expensive. Generic orlistat 120 mg is available at retail for under $100 per month. Some plans require orlistat failure before approving any branded weight-loss drug.

Switching to a covered alternative is worth discussing with the prescribing provider, particularly if the lifestyle change and weight-loss goals can be met with an oral medication at lower cost.

How a Telehealth Provider Can Help with BCBSNC Prior Authorization for Saxenda

Telehealth prescribers with experience in obesity medicine can accelerate the prior authorization process because they document clinical encounters with formulary criteria specifically in mind. A well-structured initial visit note that records BMI, qualifying comorbidities, dietary history, and prior lifestyle intervention attempts in the format BCBSNC reviewers expect reduces the back-and-forth that extends PA timelines.

BCBSNC accepts PA submissions from telehealth providers who are licensed in North Carolina and enrolled as in-network or out-of-network prescribers, provided the prescribing clinician holds an active DEA registration and North Carolina medical license where required.

Patients seeking a telehealth consultation for Saxenda or a comparable GLP-1 agent should prepare to share prior medical records, including a recent weight history covering at least 6 months, current medication list, and documentation of any past weight-loss program participation. A body weight log going back 3 to 6 months, even informal notes from a patient portal, can meaningfully support a PA request.

The 2023 American Association of Clinical Endocrinology (AACE) Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity recommend that clinicians document the degree of obesity, associated comorbidities, prior treatment history, and patient-specific barriers before initiating pharmacotherapy, precisely the documentation set that BCBSNC reviewers look for during PA review. [10]